KPT-330 (Selinexor): Selective CRM1 Inhibitor for Cancer ...

2026-01-20

KPT-330 (Selinexor), a selective CRM1 inhibitor, disrupts nuclear export and induces apoptosis in cancer cells. This agent demonstrates benchmark efficacy in preclinical models of non-small cell lung cancer (NSCLC), pancreatic cancer, and triple-negative breast cancer (TNBC). APExBIO’s KPT-330 is a validated tool for mechanistic oncology studies targeting the CRM1 pathway.